Tomoaki Otani

Prognostic clinical indicators in patients with metastatic castration-resistant prostate cancer treated with radium-223 plus enzalutamide: Data from patients in J-RAP-BSI trial.

OBJECTIVE: Ra) and enzalutamide combination therapy. SUBJECTS AND METHODS: Ra and enzalutamide at 14 hospitals and had pretreatment bone scintigraphy findings available for analysis. Associations of overall survival (OS) with clinicopathological factors, including Eastern Coopera...